Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Nepafenac 0.3% in Cataract Surgery
NCT03499873Phase 3Completed
- Sponsor
- Allergan
- Start
- Mar 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nepafenac in ocular inflammation, sponsored by Allergan. Started Mar 2018; status: completed.
02
Drugs
nepafenac
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT03499873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03499873.